Recordati Industria Chimica e Farmaceutica S.p.A. (FRA:RER1)

Market Cap	10.31B -2.9%
Revenue (ttm)	2.65B +9.9%
Net Income	471.64M +12.8%
EPS	2.25 +12.8%
Shares Out	n/a
PE Ratio	21.87
Forward PE	14.80
Dividend	1.34 (2.63%)
Ex-Dividend Date	May 18, 2026

Volume	n/a
Open	50.05
Previous Close	50.70
Day's Range	50.05 - 50.55
52-Week Range	43.42 - 55.35
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 12, 2026

About FRA:RER1

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing’s syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acety...

• Industry: Pharmaceutical Preparations
• Founded: 1926
• Employees: 4,654
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RER1

Financial Performance

In 2025, FRA:RER1's revenue was 2.62 billion, an increase of 11.82% compared to the previous year's 2.34 billion. Earnings were 443.62 million, an increase of 6.51%.